Syndax Pharmaceuticals (SNDX) Could See Upside From Entinostat in 2Q20 - Nomura/Instinet
Tweet Send to a Friend
Nomura/Instinet analyst Christopher Marai raised the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $16.00 ahead of the the Ph3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
